SKYWARD Pivotal Studies of Shockwave SkyRunner Carotid IVL Platform Begin Enrollment

June 25, 2026—Johnson & Johnson announced the initiation of its SKYWARD investigational device exemption (IDE) clinical program evaluating the company’s Shockwave SkyRunner carotid intravascular lithotripsy (IVL) system for the treatment of calcified carotid arteries when used before stenting with a commercially available transcarotid or transfemoral stent system.

STRIDE Pivotal Trial of CereVasc’s eShunt System Completes Enrollment

June 24, 2026—CereVasc, Inc. announced it has completed patient enrollment in the STRIDE pivotal trial, which is evaluating the company’s investigational eShunt system in patients with normal pressure hydrocephalus (NPH).

ESVS Focused Update of PAD Guidelines Addresses Safety Concerns of Paclitaxel

June 23, 2026—The European Society of Vascular Surgery (ESVS) announced the publication of a focused update on the ESVS peripheral artery disease (PAD) guidelines addressing the new findings on the safety of paclitaxel-coated devices.

Cook’s Volante Steerable Guiding Sheath Launched in United States

June 23, 2026—Cook Medical announced that the Volante steerable guiding sheath is now commercially available in the United States and select global markets.

Access Vascular and Medline Partner on Commercialization of Cobranded Vascular Access Catheters

June 23, 2026—Access Vascular, Inc. (AVI) and Medline announced a multiyear agreement to accelerate the rollout of AVI’s next-generation catheters, the HydroMid and HydroPICC.

Route 92’s Neurovascular Portfolio Approved in Canada

June 22, 2026—Route 92 Medical, Inc. announced that the first commercial cases in Canada were performed with the company’s neurovascular devices.

SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

ThruFlo Secures Funding to Advance Development of Its Flow Diverter for Bifurcation Aneurysms

June 16, 2026—ThruFlo Endovascular, Inc., a neuroendovascular medical device company, announced the completion of seed funding to accelerate development of its bifurcated flow diverter platform.